BMS 180291

Known as: BMS-180291, BMS180291 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-2011
0119932011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
BACKGROUND AND PURPOSE Surprisingly high contractile activity was reported for 11-deoxy-16,16-dimethyl prostaglandin E₂ (DX-DM… (More)
Is this relevant?
1998
1998
1. We tested the hypothesis that nitric oxide (NO) exerts a tonic inhibitory influence on cytochrome P450 (CYP450)-dependent… (More)
Is this relevant?
1997
1997
Domestic swine (n=12 in each group) were randomized to daily treatment with the thromboxane A2 (TXA2) receptor antagonist BMS… (More)
Is this relevant?
1996
1996
To investigate the mechanisms for intracellular signaling and increased vascular tone by 8-epi-prostaglandin F2 alpha (8-epi-PGF2… (More)
Is this relevant?
1996
1996
Thromboxane A2/prostaglandin endoperoxide receptor antagonists were studied in rat and guinea-pig aortas contracted with U-46619… (More)
Is this relevant?
1995
1995
The dose-related cardioprotective efficacy of the thromboxane A2/prostaglandin endoperoxide (TP) receptor antagonist, ifetroban… (More)
Is this relevant?
1994
1994
OBJECTIVE Studies of aortas from hypertensive and diabetic rats and rabbits have demonstrated impairment of endothelium-dependent… (More)
Is this relevant?
1994
1994
We determined the effect of thromboxane A2 (TXA2) prostaglandin endoperoxide (TP) receptor antagonism, using BMS-180291 or… (More)
Is this relevant?
1994
1994
The effects of the thromboxane A2 (TXA2)/prostaglandin endoperoxide (TP) receptor antagonist ifetroban (BMS-180291) on infarct… (More)
Is this relevant?
1993
1993
We determined the effects of aspirin and a novel thromboxane A2/prostaglandin endoperoxide (TP)-receptor antagonist, BMS-180291… (More)
Is this relevant?